Notably, Caro et al. demonstrated that this OXPHOS metabolic profile in DLBCL is associated with reduced sensitivity to BCR signaling inhibition [9], highlighting a potential interplay between metabolic adaptations and survival pathways in lymphoma development. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.